Raymond G. Booth - Publications

University of North Carolina, Chapel Hill, Chapel Hill, NC 
Pharmaceutical Chemistry, Pharmacology, Biochemistry

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Canal CE, Felsing DE, Liu Y, Zhu W, Wood JT, Perry CK, Vemula R, Booth RG. An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT7 and 5-HT1A Receptor Partial Agonist That Corrects Motor Stereotypy in Mouse Models. Acs Chemical Neuroscience. PMID 26011730 DOI: 10.1021/acschemneuro.5b00099  0.4
2015 Sakhuja R, Kondabolu K, Córdova-Sintjago T, Travers S, Vincek AS, Kim MS, Abboud KA, Fang L, Sun Z, Canal CE, Booth RG. Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors. Bioorganic & Medicinal Chemistry. 23: 1588-600. PMID 25703249 DOI: 10.1016/j.bmc.2015.01.060  0.4
2015 Kasper JM, Booth RG, Peris J. Serotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens. Synapse (New York, N.Y.). 69: 78-85. PMID 25382408 DOI: 10.1002/syn.21790  0.4
2014 Canal CE, Morgan D, Felsing D, Kondabolu K, Rowland NE, Robertson KL, Sakhuja R, Booth RG. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses. The Journal of Pharmacology and Experimental Therapeutics. 349: 310-8. PMID 24563531 DOI: 10.1124/jpet.113.212373  0.4
2013 Canal CE, Cordova-Sintjago T, Liu Y, Kim MS, Morgan D, Booth RG. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands. The Journal of Pharmacology and Experimental Therapeutics. 347: 705-16. PMID 24080681 DOI: 10.1124/jpet.113.208637  0.4
2013 Kasper J, Tikamdas R, Kim MS, Macfadyen K, Aramini R, Ladd J, Bisceglia S, Booth R, Peris J. The serotonin-2 receptor modulator, (-)-trans-PAT, decreases voluntary ethanol consumption in rats. European Journal of Pharmacology. 718: 98-104. PMID 24041931 DOI: 10.1016/j.ejphar.2013.09.008  0.4
2013 Morgan D, Kondabolu K, Kuipers A, Sakhuja R, Robertson KL, Rowland NE, Booth RG. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. Neuropharmacology. 72: 274-81. PMID 23665356 DOI: 10.1016/j.neuropharm.2013.04.051  0.4
2013 Canal CE, Booth RG, Morgan D. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology. 70: 112-21. PMID 23353901 DOI: 10.1016/j.neuropharm.2013.01.007  0.4
2012 Córdova-Sintjago T, Sakhuja R, Kondabolu K, Canal CE, Booth RG. Molecular Determinants for Ligand Binding at Serotonin 5-HT2A and 5-HT2C GPCRs: Experimental Affinity Results Analyzed by Molecular Modeling and Ligand Docking Studies. International Journal of Quantum Chemistry. 112: 3807-3814. PMID 23913978 DOI: 10.1002/qua.24237  0.4
2012 Córdova-Sintjago T, Villa N, Canal C, Booth R. Human serotonin 5-HT2C G protein-coupled receptor homology model from the β2 adrenoceptor structure: Ligand docking and mutagenesis studies International Journal of Quantum Chemistry. 112: 140-149. DOI: 10.1002/qua.23231  0.4
2011 Canal CE, Cordova-Sintjago TC, Villa NY, Fang LJ, Booth RG. Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation. European Journal of Pharmacology. 673: 1-12. PMID 22020288 DOI: 10.1016/j.ejphar.2011.10.006  0.4
2011 Ghoneim OM, Ibrahim DA, El-Deeb IM, Lee SH, Booth RG. A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual action. Bioorganic & Medicinal Chemistry Letters. 21: 6714-23. PMID 21982496 DOI: 10.1016/j.bmcl.2011.09.046  0.4
2009 Booth RG, Fang L, Huang Y, Wilczynski A, Sivendran S. (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. European Journal of Pharmacology. 615: 1-9. PMID 19397907 DOI: 10.1016/j.ejphar.2009.04.035  0.4
2008 Rowland NE, Crump EM, Nguyen N, Robertson K, Sun Z, Booth RG. Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice. Pharmacology, Biochemistry, and Behavior. 91: 176-80. PMID 18692085 DOI: 10.1016/j.pbb.2008.07.004  0.4
2008 Sansuk K, Balog CI, van der Does AM, Booth R, de Grip WJ, Deelder AM, Bakker RA, Leurs R, Hensbergen PJ. GPCR proteomics: mass spectrometric and functional analysis of histamine H1 receptor after baculovirus-driven and in vitro cell free expression. Journal of Proteome Research. 7: 621-9. PMID 18177001 DOI: 10.1021/pr7005654  0.4
2007 Booth RG, Moniri NH. Novel ligands stabilize stereo-selective conformations of the histamine H1 receptor to activate catecholamine synthesis. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 56: S43-4. PMID 17806174  1
2006 Moniri NH, Booth RG. Role of PKA and PKC in histamine H1 receptor-mediated activation of catecholamine neurotransmitter synthesis. Neuroscience Letters. 407: 249-53. PMID 16978782 DOI: 10.1016/j.neulet.2006.08.051  1
2006 Ghoneim OM, Legere JA, Golbraikh A, Tropsha A, Booth RG. Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes. Bioorganic & Medicinal Chemistry. 14: 6640-58. PMID 16782354 DOI: 10.1016/j.bmc.2006.05.077  0.4
2005 Booth RG, Moniri NH. Ligand-directed multifunctional signaling of histamine H1 receptors. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 54: S44-5. PMID 15928829 DOI: 10.1007/s00011-004-0420-z  1
2005 Heinzen EL, Booth RG, Pollack GM. Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the mu-opioid receptor. Biochemical Pharmacology. 69: 679-88. PMID 15670586 DOI: 10.1016/j.bcp.2004.11.004  0.4
2004 Moniri NH, Covington-Strachan D, Booth RG. Ligand-directed functional heterogeneity of histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling. The Journal of Pharmacology and Experimental Therapeutics. 311: 274-81. PMID 15169829 DOI: 10.1124/jpet.104.070086  1
2004 Moniri NH, Booth RG. Functional heterogeneity of histamine H(1) receptors. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 53: S71-2. PMID 15054625 DOI: 10.1007/s00011-003-0334-1  1
2002 Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. The Journal of Pharmacology and Experimental Therapeutics. 302: 328-36. PMID 12065734 DOI: 10.1124/jpet.302.1.328  0.4
2002 Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, Lawler CP, Nichols DE, Mailman RB. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. The Journal of Pharmacology and Experimental Therapeutics. 301: 1166-78. PMID 12023552 DOI: 10.1124/jpet.301.3.1166  0.4
1999 Bucholtz EC, Brown RL, Tropsha A, Booth RG, Wyrick SD. Synthesis, evaluation, and comparative molecular field analysis of 1- phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H1 receptors Journal of Medicinal Chemistry. 42: 3041-3054. PMID 10447948 DOI: 10.1021/jm980428x  0.4
1999 Booth RG, Owens CE, Brown RL, Bucholtz EC, Lawler CP, Wyrick SD. Putative sigma(3) sites in mammalian brain have histamine H(1) receptor properties: evidence from ligand binding and distribution studies with the novel H(1) radioligand [(3)H]-(-)-trans-1-phenyl-3-aminotetralin. Brain Research. 837: 95-105. PMID 10433992 DOI: 10.1016/S0006-8993(99)01602-9  0.4
1995 Wyrick SD, Booth RG, Myers AM, Owens CE, Bucholtz EC, Hooper PC, Kula NS, Baldessarini RJ, Mailman RB. 1-Phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes and related derivatives as ligands for the neuromodulatory sigma 3 receptor: further structure-activity relationships. Journal of Medicinal Chemistry. 38: 3857-64. PMID 7562917 DOI: 10.1021/jm00019a016  0.4
1994 Myers AM, Charifson PS, Owens CE, Kula NS, McPhail AT, Baldessarini RJ, Booth RG, Wyrick SD. Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor. Journal of Medicinal Chemistry. 37: 4109-17. PMID 7990111 DOI: 10.1021/jm00050a008  0.4
1994 Wyrick SD, Myers AM, Booth RG, Kula NS, Baldessarini RJ, Mailman RB. Synthesis of [N-C3H3]-trans-(1R,3S)-(-)-1-phenyl-3-N,N-dimethylamino-1,2,3,4-tetr ahydronaphthalene (H2-PAT) Journal of Labelled Compounds and Radiopharmaceuticals. 34: 131-134. DOI: 10.1002/jlcr.2580340205  0.4
1993 Wyrick SD, Booth RG, Myers AM, Owens CE, Kula NS, Baldessarini RJ, McPhail AT, Mailman RB. Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel receptor with sigma-like neuromodulatory activity. Journal of Medicinal Chemistry. 36: 2542-51. PMID 8102651 DOI: 10.1021/jm00069a013  0.4
1992 Wyrick SD, Booth RG, Myers AM, Kula NS, Baldessarini RJ. Synthesis of [N-C3H3]-racemic-trans-1-phenyl-3-dimethylamino-6-chloro-7-hydroxy- 1,2,3,4-tetrahydronaphthalene (PAT-6) Journal of Labelled Compounds and Radiopharmaceuticals. 31: 871-874. DOI: 10.1002/jlcr.2580311106  0.4
1991 Teicher MH, Gallitano AL, Gelbard HA, Evans HK, Marsh ER, Booth RG, Baldessarini RJ. Dopamine D1 autoreceptor function: possible expression in developing rat prefrontal cortex and striatum. Brain Research. Developmental Brain Research. 63: 229-35. PMID 1686425 DOI: 10.1016/0165-3806(91)90082-T  0.4
1990 Booth RG, Baldessarini RJ, Kula NS, Neumeyer JL. Stereochemical effects of mono- and dihydroxyaporphines on presynaptic inhibition of dopamine synthesis in vitro Annals of the New York Academy of Sciences. 604: 592-595. DOI: 10.1111/j.1749-6632.1990.tb32034.x  0.4
1989 Booth RG, Trevor A, Singer TP, Castagnoli N. Studies on semirigid tricyclic analogues of the nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Journal of Medicinal Chemistry. 32: 473-7. PMID 2783613 DOI: 10.1021/jm00122a031  0.4
1988 Sirawaraporn W, Sertsrivanich R, Booth RG, Hansch C, Neal RA, Santi DV. Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by 5-benzyl-2,4-diaminopyrimidines Molecular and Biochemical Parasitology. 31: 79-85. PMID 3185614 DOI: 10.1016/0166-6851(88)90147-8  0.4
1987 Booth RG, Selassie CD, Hansch C, Santi DV. Quantitative structure-activity relationship of triazine-antifolate inhibition of Leishmania dihydrofolate reductase and cell growth Journal of Medicinal Chemistry. 30: 1218-1224. PMID 3599028 DOI: 10.1021/jm00390a017  0.4
1987 Ramsay RR, McKeown KA, Johnson EA, Booth RG, Singer TP. Inhibition of NADH oxidation by pyridine derivatives. Biochemical and Biophysical Research Communications. 146: 53-60. PMID 2886124 DOI: 10.1016/0006-291X(87)90689-9  0.4
Show low-probability matches.